Internship

Managed Care Science Liaison Intern

Posted on 12/20/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

San Diego, CA, USA

Work from HQ offices in San Diego.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Pursuing a graduate degree with an interest in biotechnology
  • Specific degree or field required: PharmD or PhD
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes is desirable
  • Good verbal and written communication skills
  • Ability to think creatively and be a team player
  • Offer flexibility with a willingness to work on multiple projects simultaneously
  • Bring to the Company a skill set complementary to its technology and development therapeutics
  • Interest in attending various program events, including social gatherings, career development workshops, and off-site team meetings
  • Ability to commit to a 10-week, full-time summer program
  • Work from HQ offices in San Diego but capitalize on opportunities for travel (field rides)
Responsibilities
  • Supporting a range of activities, including interactions with payors and organized customers
  • Medicaid Testimony
  • Field Medical Resources
  • Launch Activities
  • Formulary Meetings
  • Interacting with Managed Care Liaisons, Medical Science Liaisons and Health Economics Research areas within the company
  • Collaborating with cross-functional team members as well as the other interns at Neurocrine
  • Completing a special project and presenting the recommendations to senior management upon completion
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY opens a new market for CAH treatment.
  • Positive Phase 2 data for NBI-1117568 boosts Neurocrine's mental health portfolio.
  • Recognition as a top workplace enhances Neurocrine's reputation and employee satisfaction.

What critics are saying

  • Increased competition in CAH treatment may impact CRENESSITY's market share.
  • Potential market saturation for INGREZZA due to similar products.
  • CEO transition could lead to strategic misalignment.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first new CAH treatment in 70 years.
  • INGREZZA SPRINKLE offers a unique formulation for patients with swallowing difficulties.
  • Neurocrine's NBI-1117568 shows promising results for schizophrenia treatment.

Help us improve and share your feedback! Did you find this helpful?